NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Q3 2022 Earnings Conference Call November 14, 2022 8:00 AM ET

Company Participants

Suzanne Messere - Investor Relations

Stephen Willard - Chief Executive Officer

Seth Van Voorhees - Chief Financial Officer and Treasurer

Jonathan Javitt - Founder and Chief Scientist

Conference Call Participants

Vernon Bernadino - H.C. Wainwright

Ed Woo - Ascendiant Capital

Operator

Good morning, and welcome to the NRx Pharmaceuticals Third Quarter 2022 Earnings Conference Call. All participants will be in listen-only mode. [Operator Instructions] After today's presentation, there will be an opportunity to ask questions. [Operator Instructions] Please note this event is being recorded.

I would now like to turn the conference over to Suzanne Messere with Stern Investor Relations. Please, go ahead.

Suzanne Messere

Thank you, Andrea. Before we proceed with the call, I would like to remind everyone that certain statements made during this call are forward-looking statements under U.S. Federal Securities Laws. These statements are subject to risks and uncertainties that could cause actual results to differ materially from historical experience or present expectations. Additional information concerning factors that could cause actual results to differ from statements made on this call is contained in our periodic reports filed with the SEC.

The forward-looking statements made during this call's speak only as the date hereof. And the company undertakes no obligation to update or revise the forward-looking statements. Information presented on this call is contained in the press release issued earlier today and in the company's Form 10-Q being filing today as well, which maybe accessed from the investor's page of the NRx Pharmaceuticals website.

Joining me on today's call from NRx Pharmaceuticals are Stephen Willard, Chief Executive Officer, and Seth Van Voorhees, Chief Financial Officer and Treasurer. Stephen will provide a summary of the company's progress; Seth the review of the company's financial results, and then Stephen will review upcoming milestones before making closing comments and opening up for questions. During the Q&A session, Stephen and Seth will be joined Robert Besthof, Head of Operations and Chief Commercial Officer; and Jonathan Javitt, the Company's Chief Scientific Officer to address investor questions.

I will now turn the call over to Stephen.

Stephen Willard

Thank you, Suzanne. Good morning, everyone, and thank you for joining us. Today we will discuss the third quarter results for our company and provide a business update. In March, we announced that our primary strategic focus going forward is on our psychiatry franchise and the late-stage development of NRX-101, our lead investigational compound.